VENOUS THROMBOEMBOLISM IN MULTIPLE MYELOMA. A POPULATION-BASED STUDY ON 8672 MULTIPLE MYELOMA PATIENTS DIAGNOSED 2008 -2021 FROM THE SWEDISH MYELOMA REGISTRY

EHA Library, Mariana Villegas-Scivetti, 420969

EFFICACY AND SAFETY OF ELRANATAMAB MONOTHERAPY IN THE REAL-WORD SETTING IN RELAPSED-REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS OF THE FRENCH COMPASSIONATE USE PROGRAM ON BEHALF OF THE IFM

EHA Library, Mohamad Mohty, 420970

KTD OR KRD INDUCTION FOLLOWED BY K MAINTENANCE OR OBSERVATION IN TRANSPLANT INELIGIBLE (TIE) PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (MM). FINAL ANALYSIS OF THE AGMT MM02 TRIAL

EHA Library, Heinz Ludwig, 420971

ANTI-CD38 ANTIBODY RETREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA PREVIOUSLY TREATED WITH LENALIDOMIDE AND AN ANTI-CD38 ANTIBODY: REAL-WORLD DATA USING THE US FLATIRON DATABASE

EHA Library, Andrew J. Cowan, 420972

PATIENTS WITH MULTIPLE MYELOMA - WHAT HAPPENS IN SECOND LINE AFTER FIRST-LINE LENALIDOMIDE? DATA FROM THE GERMAN MYRIAM REGISTRY

EHA Library, Patrick Marschner, 420973

LOW-DOSE VENETOCLAX-DEXAMETHASONE IN T(11;14)-POSITIVE RELAPSED AND REFRACTORY MULTIPLE MYELOMA; INTERIM RESULTS OF THE ONGOING, DANISH, INVESTIGATOR-INITIATED, PHASE 2 VICTORIA STUDY

EHA Library, Agoston Gyula Szabo, 420974

TALQUETAMAB, A GPRC5D×CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH POMALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: SAFETY AND EFFICACY RESULTS FROM THE PHASE 1B MONUMENTAL-2 STUDY

EHA Library, Emma Searle, 420975

EFFICACY OF VENETOCLAX-DEXAMETHASONE V POMALIDOMIDE-DEXAMETHASONE IN PATIENTS WITH T(11;14)-POSITIVE RELAPSED/REFRACTORY MULTIPLE MYELOMA [T(11;14)+ RRMM]:PHASE 3 CANOVA BIOMARKER SUBGROUP ANALYSIS

EHA Library, Nizar J Bahlis, 420976

REAL-LIFE OUTCOMES IN PATIENTS (PTS) WITH BCMA-EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH STANDARD OF CARE (SOC) IN THE LOCOMMOTION AND MOMMENT STUDIES

EHA Library, Katja Weisel, 420977

VACCINATING AGAINST MUTATED RAS IN MULTIPLE MYELOMA: THE PHASE I/II TG01 STUDY

EHA Library, Hanne Norseth, 420978

LONG-TERM EFFICACY AND SAFETY RESULTS FROM THE PHASE 1/2 MONUMENTAL-1 STUDY OF TALQUETAMAB, A GPRC5D×CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Leo Rasche, 420979

ALL-ORAL TRIPLET IBERDOMIDE IXAZOMIB AND DEXAMETHASONE IN ELDERLY PATIENTS WITH MULTIPLE MYELOMA AT FIRST RELAPSE: RESULTS OF THE IFM PHASE 2 STUDY I2D

EHA Library, Cyrille Touzeau, 420980

LISAFTOCLAX (APG-2575) COMBINED WITH NOVEL THERAPEUTIC REGIMENS IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) MULTIPLE MYELOMA (MM) OR IMMUNOGLOBULIN LIGHT-CHAIN (AL) AMYLOIDOSIS

EHA Library, Sikander Ailawadhi, 420981

REAL-WORLD CARFILZOMIB PRESCRIBING PATTERNS AND OUTCOMES FOR PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Sharlene Dong, 420982

FUNCTIONAL ASSESSMENTS INCLUDING SARCOPENIA BETTER DETECT FRAILTY THAN THE IMWG FRAILTY SCORE AND IMPROVE PREDICTION OF OUTCOME IN MULTIPLE MYELOMA

EHA Library, Febe Smits, 420983

SAFETY RESULTS FROM THE PHASE 3 MAJESTEC-7 STUDY IN PATIENTS WITH TRANSPLANT INELIGIBLE/NOT INTENDED NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)

EHA Library, Niels W.C.J. van de Donk, 420984

CARDIAC RESPONSE DYNAMICS IN NEWLY DIAGNOSED LIGHT-CHAIN AMYLOIDOSIS PATIENTS WHO ACHIEVED A HIGH-QUALITY HEMATOLOGIC RESPONSE WITHIN THREE MONTHS

EHA Library, Chengyang Xu, 420985

OUTCOMES OF PATIENTS WITH EXTRAMEDULLARY DISEASE AND RELAPSED OR REFRACTORY MULTIPLE MYELOMA FROM HISTORICAL CLINICAL TRIALS

EHA Library, Shaji Kumar, 420986

EFFICACY AND SAFETY OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WITH HIGH-RISK FEATURES: A SUBGROUP ANALYSIS FROM THE PHASE 1/2 MAJESTEC-1 STUDY

EHA Library, Luciano J. Costa, 420987

IMPROVED ACCURACY OF MONOCLONAL IMMUNOGLOBULIN MEASUREMENT BY EXENT MASS SPECTROMETRY IN PATIENTS WITH MULTIPLE MYELOMA AND KIDNEY FAILURE: ANALYSIS FROM THE EULITE TRIAL

EHA Library, Graham McIlroy, 420988

INCLUSION CRITERIA OF CLINICAL TRIALS SELECT PATIENTS WITH AL AMYLOIDOSIS WITH FAVORABLE OUTCOME AND EXCLUDE ALMOST ONE HALF OF THE REAL-LIFE POPULATION

EHA Library, Claudia Bellofiore, 420989

THE NEED FOR REDUCING RELAPSE RISK IN CYTOGENETICALLY HIGH-RISK MULTIPLE MYELOMA: IMPROVING OR OPTIMIZING MAINTENANCE MANAGEMENT

EHA Library, Xinyuan Gu, 420991

CLINICAL PRESENTATION AND OUTCOMES OF PATIENTS WITH MONOCLONAL GAMMOPATHY OF RENAL SIGNIFICANCE (MGRS): A MULTICENTRIC RETROSPECTIVE STUDY

EHA Library, Katia Mancuso, 420992

EFFECTIVENESS AND SAFETY OF BISPECIFIC ANTIBODIES TARGETING BCMA AND CD3 IN PATIENTS WITH CENTRAL NERVOUS SYSTEM MULTIPLE MYELOMA (CNS-MM): IFM 2023-06, A RETROSPECTIVE COHORT STUDY.

EHA Library, Florence Lachenal, 420993

DISEASE CHARACTERISTICS AND SURVIVAL OUTCOMES IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA BY EXTRAMEDULLARY DISEASE STATUS: FINDINGS FROM THE CONNECT® MM DISEASE REGISTRY

EHA Library, Hans Lee, 420994

IXAZOMIB, POMALIDOMIDE AND DEXAMETHASONE (IXPD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) CHARACTERIZED WITH HIGH-RISK CYTOGENETICS. IFM 2014-01

EHA Library, Arthur Bobin, 420995

LONG-TERM SURVIVAL AFTER ELRANATAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): MAGNETISMM-3

EHA Library, Mohamad Mohty, 420996

EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT-CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK

EHA Library, Efstathios Kastritis, 420997

LONGER-TERM FOLLOW-UP OF PATIENTS RECEIVING PROPHYLACTIC TOCILIZUMAB FOR REDUCTION OF CYTOKINE RELEASE SYNDROME IN THE PHASE 1/2 MAJESTEC-1 STUDY OF TECLISTAMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Katarina Uttervall, 420998

CHARACTERISTICS AND CLINICAL OUTCOMES OF PATIENTS WITH TRIPLE-CLASS EXPOSED MULTIPLE MYELOMA ACROSS EUROPE: RESULTS FROM THE HARMONY ALLIANCE BIG DATA PLATFORM

EHA Library, Carlos López, 420999

PREDICTORS OF LIVER RESPONSE KINETICS IN LIGHT CHAIN (AL) AMYLOIDOSIS

EHA Library, Matthew Rees, 421000

REAL WORLD OUTCOMES WITH ELOTUZUMAB-BASED THERAPIES FOR PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM): A MAYO CLINIC EXPERIENCE

EHA Library, Ricardo Parrondo, 421001

DREAMM-7 UPDATE: SUBGROUP ANALYSES FROM A PHASE 3 TRIAL OF BELANTAMAB MAFODOTIN + BORTEZOMIB AND DEXAMETHASONE VS DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, María-Victoria Mateos, 421002

IMPROVED DISEASE STATUS PRE-INFUSION LEADS TO BETTER OUTCOMES WITH STANDARD OF CARE IDECABTAGENE VICLEUCEL (IDE-CEL) IN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Aimaz Afrough, 421003

RELAPSE FROM MEASURABLE DISEASE NEGATIVITY AS INDICATION FOR TREATMENT IN MULTIPLE MYELOMA: THE PHASE 3 REMNANT STUDY

EHA Library, Frida Bugge Askeland, 421004

FIRST-IN-HUMAN STUDY OF GPRC5D-TARGETED CAR T CELLS (CT071) WITH AN ACCELERATED MANUFACTURING PROCESS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Juan Du, 421005

LONG-TERM FOLLOW-UP FROM THE PHASE 1/2 MAJESTEC-1 TRIAL OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Albert Oriol, 421006

ORAL IXAZOMIB MAINTENANCE FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): FINAL OVERALL SURVIVAL (OS) ANALYSIS FROM THE TOURMALINE-MM3 STUDY

EHA Library, Meletios Dimopoulos, 421007

DIFFERENTIAL PROGNOSTIC OUTCOMES IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH DISTINCT HIGH-RISK CYTOGENETIC ABNORMALITY COMBINATIONS

EHA Library, Juan Li, 421008

PATIENT-REPORTED OUTCOMES FROM DREAMM-7 A RANDOMIZED PHASE 3 STUDY OF BELANTAMAB MAFODOTIN, BORTEZOMIB + DEXAMETHASONE (DEX) VS DARATUMUMAB, BORTEZOMIB + DEX IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Vania Hungria, 421009

COMPARATIVE EFFECTIVENESS OF LINVOSELTAMAB VERSUS STANDARD-OF-CARE TREATMENT IN REAL-WORLD PATIENTS IN THE UNITED STATES WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Katja Weisel, 421010

LONG-TERM FOLLOW UP DEFINES THE POPULATION THAT BENEFITS FROM EARLY INTERCEPTION IN HIGH-RISK SMOLDERING MULTIPLE MYELOMA USING THE COMBINATION OF IXAZOMIB, LENALIDOMIDE, AND DEXAMETHASONE

EHA Library, Omar Nadeem, 421011

SPECTRUM AND DURATION OF INFECTIOUS COMPLICATIONS IN PATIENTS TREATED WITH BCMA- AND GPRC5D-TARGETED IMMUNOTHERAPIES IN MULTIPLE MYELOMA

EHA Library, Julia Mersi, 421012

TIMING AND OUTCOMES OF SECOND LINE THERAPY IN THE ERA OF DARATUMUMAB-BASED FRONTLINE THERAPY IN AL AMYLOIDOSIS

EHA Library, Abdul-Hamid Bazarbachi, 421013

CHARACTERISICS AND OUTCOMES OF PATIENTS WITH FUNCTIONAL HIGH RISK MULTIPLE MYELOMA FROM THE HONEUR FEDERATED DATA NETWORK

EHA Library, Yael Cohen, 421014

SAFETY AND PRELIMINARY EFFICACY OF BMS-986393, A GPRC5D CAR T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY (RR) MULTIPLE MYELOMA (MM) AND 1–3 PRIOR REGIMENS: FIRST RESULTS FROM A PHASE 1 STUDY

EHA Library, Omar Nadeem, 421015

LIGHT CHAIN SMOLDERING MULTIPLE MYELOMA – THE MISSING LINK: RESULTS FROM THE SCREENED ISTOPMM STUDY

EHA Library, Sigrún Thorsteinsdóttir, 421016

EFFICACY AND SAFETY OF DARATUMUMAB MONOTHERAPY IN NEWLY DIAGNOSED PATIENTS WITH STAGE 3B LIGHT-CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK

EHA Library, Efstathios Kastritis, 421017

LONG-TERM OUTCOMES OF NEWLY DIAGNOSED POEMS SYNDROME PATIENTS WHO RECEIVED FIRST-LINE LENALIDOMIDE-BASED THERAPY

EHA Library, Xuemin Gao, 421018

ADVANCING PERSONALIZED THERAPY IN MULTIPLE MYELOMA: MACHINE LEARNING-DRIVEN RISK STRATIFICATION FOR PREDICTING OUTCOMES WITH BELANTAMAB MAFODOTIN MONOTHERAPY

EHA Library, Adrian Mosquera-Orgueira, 421019

MULTIVARIABLE RISK STRATIFICATION REFINES THE CURRENT IMWG DIAGNOSTIC CRITERIA FOR PLASMA CELL LEUKEMIA

EHA Library, Jessica Peter, 421020

A PHASE 2 STUDY OF ISATUXIMAB IN COMBINATION WITH BORTEZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE, FOLLOWED BY ISATUXIMAB AND LENALIDOMIDE MAINTENANCE IN NDMM PATIENTS WITH SEVERE RENAL IMPAIRMENT

EHA Library, Evangelos Terpos, 421021

IBERDOMIDE MAINTENANCE AFTER AUTOLOGOUS STEM-CELL TRANSPLANTATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: AN UPDATE FROM THE PHASE 2 EMN26 TRIAL

EHA Library, Francesca Gay, 421022

CILTACABTAGENE AUTOLEUCEL VS STANDARD OF CARE IN PATIENTS WITH FUNCTIONAL HIGH-RISK MULTIPLE MYELOMA: CARTITUDE-4 SUBGROUP ANALYSIS

EHA Library, Katja Weisel, 421023

SHOULD WE ADOPT THE NEW ISTOPMM BASED CRITERIA FOR LC-MGUS?

EHA Library, Dor Shpitzer, 421024

A PHASE I MONOTHERAPY STUDY ASSESSING THE SAFETY AND EFFICACY OF GR1803, A BCMA×CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Jie Jin, 421025

CURRENT USE OF BCMA-TARGETED AGENTS IN RELAPSED/REFRACTORY MULTIPLE MYELOMA AND KEY DRIVERS WHEN SELECTING CAR T-CELLS VERSUS BISPECIFICS. DATA FROM REAL-WORLD STUDY IN EU5 COUNTRIES AND IN THE US

EHA Library, Nicolas Blin, 421026

OPTIMIZING THE ACADEMIC ANTI-BCMA CAR CARTEMIS-1: ASSESSING THE IMPACT OF MANUFACTURING PROCEDURE ON CAR-T CELL FEATURES

EHA Library, Belén Sierro Martínez, 421027

THE PROGNOSTIC IMPACT OF THE PRESENCE OF T(11;14) IN NEWLY DIAGNOSED MYELOMA PATIENTS IS TREATMENT DEPENDENT: AN ANALYSIS OF THE BALKAN MYELOMA STUDY GROUP

EHA Library, Efstathios Kastritis, 421028

SAFETY AND EFFICACY ANALYSIS OF GPRC5D-TARGETED CAR-T CELL THERAPY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS

EHA Library, Shiqi Li, 421029

SAFETY AND UTILITY OF BISPECIFIC MONOCLONAL ANTIBODIES AS SALVAGE THERAPY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS PREVIOUSLY TREATED WITH CAR-T CELLS

EHA Library, Luis-Esteban Tamariz-Amador, 421030

COMPARATIVE EFFECTIVENESS OF CILTACABTAGENE AUTOLEUCEL FROM THE CARTITUDE-4 TRIAL VS REAL-WORLD PHYSICIAN'S CHOICE OF THERAPY FROM THE FLATIRON REGISTRY IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA

EHA Library, Cyrille Touzeau, 421031

FINAL SURVIVAL ANALYSIS OF DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS LENALIDOMIDE AND DEXAMETHASONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: MAIA STUDY

EHA Library, Thierry Facon, 421032

LOW SOCIO-ECONOMIC STATUS IS ASSOCIATED WITH REDUCED ACCESS TO QUALITY HEALTHCARE IN MULTIPLE MYELOMA; A POPULATION-BASED STUDY

EHA Library, Flores Weverling, 421033

PRE-EMPTIVE DARATUMUMAB TREATMENT IN ASYMPTOMATIC BIOCHEMICAL RELAPSE CAN PROLONG SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA: RESULTS OF THE RANDOMIZED, MULTICENTER PREDATOR-BR CLINICAL TRIAL

EHA Library, Krzysztof Jamroziak, 421034

EFFICACY AND SAFETY OF IXAZOMIB PLUS LENALIDOMIDE AS MAINTENANCE FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION(ASCT) IN HIGH RISK NEWLY DIAGNOSED MULTIPLE MYELOMA(NDMM）

EHA Library, Yang Liu, 421035

ASSESSING FRAILTY IN MYELOMA: THE PURSUIT OF SIMPLICITY MAY SACRIFICE PRECISION OF PREDICTING CLINICAL OUTCOMES

EHA Library, Kaz Groen, 421036

BRIDGING STRATEGIES FOR ANTI-BCMA CAR-T CELL THERAPIES IN MULTIPLE MYELOMA PATIENTS WITH PRIOR EXPOSURE TO BISPECIFIC ANTIBODIES

EHA Library, Johannes Waldschmidt, 421037

DARATUMUMAB (DARA)/BORTEZOMIB/LENALIDOMIDE/DEXAMETHASONE (D-VRD) WITH D-R MAINTENANCE (MAINT) IN TRANSPLANT-ELIGIBLE (TE) NEWLY DIAGNOSED MYELOMA (NDMM): ANALYSIS OF PERSEUS BASED ON CYTOGENETIC RISK

EHA Library, Meletios Dimopoulos, 421038

MONOCLONAL PROTEIN DETECTION BY LIQUID CHROMATOGRAPHY MASS SPECTROMETRY (LC-MS) FOR IDENTIFICATION OF EXCEPTIONAL RESPONDERS IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)

EHA Library, Andrzej Jakubowiak, 421039

METABOLIC SYNDROME AND THE RISK OF MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE: A POPULATION-BASED SCREENING STUDY IN ICELAND

EHA Library, Kristján Berg Guðmundsson, 421040

IMPACT OF DARA-VTD INDUCTION THERAPY ON HEMATOPOIETIC STEM CELL COLLECTION AND ENGRAFTMENT IN MULTIPLE MYELOMA PATIENTS ELIGIBLE FOR ASCT: RESULTS OF THE PRIMULA STUDY

EHA Library, Vanda Strafella, 421041

CILTACABTAGENE AUTOLEUCEL VS STANDARD OF CARE IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA: PHASE 3 CARTITUDE-4 SUBGROUP ANALYSIS BY CYTOGENETIC RISK

EHA Library, Roberto Mina, 421042

PROSPECTIVE EVALUATION OF 3T WHOLE-BODY MRI AND 18F-FDG PET/CT IN THE MANAGEMENT OF MULTIPLE MYELOMA AND SMOLDERING MYELOMA

EHA Library, Claudio Cerchione, 421043

ISATUXIMAB CYCLOPHOSPHAMIDE BORTEZOMIB AND DEXAMETHASONE INDUCTION AND AUTOLOGOUS STEM CELL TRANSPLANT IN NEWLY DIAGNOSED MYELOMA: REPORT OF THE PROSPECTIVE CANADIAN MYELOMA RESEARCH GROUP 008 TRIAL

EHA Library, Rami Kotb, 421044

EVALUATION OF CYTOKINE RELEASE SYNDROME IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA RECEIVING STEP-UP PRIMING DOSES AND LONGER DOSING INTERVALS OF ELRANATAMAB: MAGNETISMM-9

EHA Library, Charlotte Pawlyn, 421045

PHASE 1/2 TRIAL TO JOINTLY OPTIMIZE DOSE AND ADMINISTRATION SCHEDULE OF EVOMELA IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS UNDERGOING AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION

EHA Library, Qaiser Bashir, 421046

BOTH SINGLE AND BIALLELIC TP53 ABERRATIONS PREDICT POOR PROGNOSIS IN MULTIPLE MYELOMA

EHA Library, Romana Nesnadná, 421047

RADIATION THERAPY IN THE MODERN ERA OF MULTIPLE MYELOMA MANAGEMENT: TRENDS OF RT INTEGRATION, PATTERNS OF UTILIZATION, AND RADIOLOGIC, BIOCHEMICAL, AND CYTOGENETIC CORRELATES OF OUTCOME AND RESPONSE

EHA Library, Alexandra Dreyfuss, 421048

COMBINED MASS SPECTROMETRY AND NEXT GENERATION FLOW AS EARLY PREDICTORS OF RESPONSE IN RELAPSED/REFRACTORY MYELOMA PATIENTS TREATED WITH CAR-T CELLS AND T-CELL ENGAGERS

EHA Library, Noemi Puig, 421049

THE PROGNOSTIC IMPACT OF DIFFERENTIAL CIRCULATING TUMOR CELL COUNT IN NEWLY DIAGNOSED PATIENTS WITH AL AMYLOIDOSIS, ASSESSED WITH NEXT-GENERATION FLOW CYTOMETRY

EHA Library, Ioannis Kostopoulos, 421050

A SINGLE-ARM PHASE 2 STUDY EVALUATING THE OPTIMIZED SCHEDULE OF BELANTAMAB MAFODOTIN 1.9 MG/KG Q8W PLUS BORTEZOMIB AND DEXAMETHASONE IN RELAPSED REFRACTORY MULTIPLE MYELOMA

EHA Library, Tereza Popková, 421051

DEVELOPMENT OF A COMPREHENSIVE PROGNOSTIC STRATIFICATION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA INTEGRATING MULTIDIMENSIONAL FACTORS

EHA Library, Lulu Wang, 421052

PROGNOSTIC SIGNIFICANCE OF 1Q21 CHROMOSOMAL ABNORMALITIES IN CLINICAL PRACTICE:  GAIN OR AMPLIFICATION 1Q21 IN MULTIPLE MYELOMA – WHICH ONE IS WORSE?

EHA Library, Aleksandra Sretenovic, 421053

REAL-WORLD SCHEDULE DE-ESCALATION OF TECLISTAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA – A US NATIONAL HEALTHCARE CLAIMS ANALYSIS

EHA Library, Matthew J. Pianko, 421054

STEM CELL BOOST FOR PERSISTENT CYTOPENIAS AFTER BCMA-DIRECTED CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELL THERAPY

EHA Library, Anupama Kumar, 421055

TECLISTAMAB (TEC) STEP-UP DOSING (SUD) AND TREATMENT DOSE SCHEDULE DE-ESCALATION IN THE REAL-WORLD (RW) SETTING – AN ANALYSIS OF MULTICENTER ELECTRONIC MEDICAL RECORDS

EHA Library, Rahul Banerjee, 421056

FINAL RESULTS OF A PHASE 1 STUDY OF DARATUMUMAB, IXAZOMIB, AND DEXAMETHASONE IN NEWLY DIAGNOSED AND PREVIOUSLY TREATED AL AMYLOIDOSIS

EHA Library, Hans Lee, 421057

ASSESSING THE ROLE OF PRACTICE SETTING ON DISPARITIES IN CLINICAL AND TREATMENT OUTCOMES AMONG PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)

EHA Library, Aster Meche, 421058

SYNCHRONOUS AND SECOND PRIMARY CANCERS IN NEWLY DIAGNOSED MULTIPLE MYELOMA NON-TRANSPLANT-ELIGIBLE TREATED WITH LENALIDOMIDE.

EHA Library, Thomas Systchenko, 421059

LONG TERM OUTCOME OF A SEQUENTIAL RESPONSE-DRIVEN BORTEZOMIB-BASED THERAPY FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT IN AL AMYLOIDOSIS

EHA Library, Marco Basset, 421060

ADAPTIVE FREQUENTIST DESIGNS IN THE RANDOMIZED HOVON-87/NMSG18 CLINICAL TRIAL FOR PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Maarten Seefat, 421061

REAL-WORLD DATA ON THE DARATUMUMAB PLUS BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY LENALIDOMIDE MAINTENANCE FOR TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS

EHA Library, Edvan Crusoe, 421062

NOVEL SELINEXOR TRIPLET AND QUADRUPLET REGIMENS (SND, SPED, SBD, SDPD): RESULTS FROM THE PHASE 1B/2 STOMP MULTIPLE MYELOMA TRIAL

EHA Library, Sumit Madan, 421063

COMPARATIVE ANALYSIS OF NEXT-GENERATION SEQUENCING AND OPTICAL GENOME MAPPING TECHNOLOGIES FOR DETECTING STRUCTURAL VARIANTS AND COPY NUMBER VARIANTS IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA

EHA Library, Marta Portasany, 421064

ASSOCIATION BETWEEN DICER1 RS3742330 AND AGO1 RS636832 POLYMORPHISMS AND ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN AND ADOLESCENTS FROM GREECE: A CASE-CONTROL STUDY

EHA Library, Ioannis Kyriakidis, 421065

RNA-SEQ IS A RELIABLE METHODOLOGY FOR THE RECLASSIFICATION OF PEDIATRIC B-OTHER ACUTE LYMPHOBLASTIC LEUKEMIA INTO NEW GENETIC SUBTYPES

EHA Library, Clara Vicente Garcés, 421066

EXPLORING THE GENOMIC FEATURES OF CML-LIKE PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA

EHA Library, Fatemah Rezayee, 421067

TRANSCRIPTOMIC LANDSCAPE OF DUX4-REARRANGED B-ALL IN INDIA

EHA Library, Mercilena Benjamin, 421068

DOES MENINGEAL INFILTRATION HEIGHTEN INFLAMMATORY RESPONSE IN B-ACUTE LYMPHOBLASTIC LEUKEMIA?

EHA Library, eya anane, 421069